Advances of berberine against metabolic syndrome-associated kidney disease: Regarding effect and mechanism

The prevalence of metabolic syndrome (MetS) is drastically growing worldwide, resulting in MetS-associated kidney disease. According to traditional theories, preventing blood pressure, lipid, glycose, and obesity and improving insulin resistance (IR), a couple of medications are required for MetS. I...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 14; p. 1112088
Main Authors Liu, Ya-Fei, Wang, Huan-Huan, Geng, Yin-Hong, Han, Liang, Tu, Sheng-Hao, Wang, Hui
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 06.02.2023
Subjects
berberine
diabetic nephropathy
hyperlipidemia
insulin resistance
metabolic syndrome
obesity
Pharmacology
metabolic syndrome
hyperlipidemia
kidney disease
insulin resistance
diabetic nephropathy
obesity
berberine
Online AccessGet full text

Cover

More Information
Summary:The prevalence of metabolic syndrome (MetS) is drastically growing worldwide, resulting in MetS-associated kidney disease. According to traditional theories, preventing blood pressure, lipid, glycose, and obesity and improving insulin resistance (IR), a couple of medications are required for MetS. It not only lowers patients' compliance but also elevates adverse reactions. Accordingly, we attempted to seek answers from complementary and alternative medicine. Ultimately, berberine (BBR) was chosen due to its efficacy and safety on MetS through multi-pathways and multi-targets. The effects and mechanisms of BBR on obesity, IR, diabetic nephropathy, hypertension, hyperlipidemia, and hyperuricemia were elaborated. In addition, the overall properties of BBR and interventions for various kidney diseases were also collected. However, more clinical trials are expected to further identify the beneficial effects of BBR.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Dan Li, Chengdu University of Traditional Chinese Medicine, China
Edited by: Weidong Xie, Tsinghua University, China
Qingsheng Liu, Hangzhou Hospital of Traditional Chinese Medicine, China
This article was submitted to Renal Pharmacology, a section of the journal Frontiers in Pharmacology
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2023.1112088